Literature DB >> 149046

Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251.

P Friberger, M Knös, S Gustavsson, L Aurell, G Claeson.   

Abstract

The chromogenic substrate S-2251 (H-D-Val-Leu-Lys-pNA), a selective and sensitive substrate for plasmin activity, has made it possible to develop simple and reproducible methods for the determination of antiplasmin and plasminogen in human plasma. These methods have been optimized and studied in detail and found to be very specific for the respective factors.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 149046     DOI： 10.1159/000214252

Source DB:  PubMed          Journal:  Haemostasis        ISSN： 0301-0147


  37 in total

1.  Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.

Authors:  I Y Sazonova; R A McNamee; A K Houng; S M King; L Hedstrom; G L Reed
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

2.  Plasminogen in proliferative vitreoretinal disorders.

Authors:  P Esser; K Heimann; K U Bartz-Schmidt; P Walter; R Krott; M Weller
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

3.  The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity.

Authors:  Jérôme Devy; Farid Ouchani; Christelle Oudot; Jean Jacques Helesbeux; Enguerran Vanquelef; Stéphanie Salesse; Fanja Rabenoelina; Siana Al-Khara; Isabelle Letinois; Olivier Duval; Laurent Martiny; Emmanuelle Charpentier
Journal:  Invest New Drugs       Date:  2010-03-28       Impact factor: 3.850

4.  Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.

Authors:  J P Monassier; M Hanssen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion.

Authors:  R D Shlansky-Goldberg; A H Matsumoto; G A Baumbach; J B Siegel; R D Raabe; T P Murphy; C Deng; J Ray Dawkins; V J Marder
Journal:  J Thromb Haemost       Date:  2008-04-02       Impact factor: 5.824

6.  Age-related effects of regular physical activity on hemostatic factors in men.

Authors:  Jun Sugawara; Koichiro Hayashi; Sumiko Kurachi; Taku Tanaka; Takashi Yokoi; Kotoku Kurachi
Journal:  J Thromb Thrombolysis       Date:  2007-09-10       Impact factor: 2.300

7.  Ascites-induced LeVeen shunt coagulopathy.

Authors:  M V Ragni; J H Lewis; J A Spero
Journal:  Ann Surg       Date:  1983-07       Impact factor: 12.969

8.  Expression profiles of fibrinolytic components in nasal mucosa.

Authors:  Takayuki Sejima; Seiji Madoiwa; Jun Mimuro; Teruko Sugo; Takashi Ishida; Keiichi Ichimura; Yoichi Sakata
Journal:  Histochem Cell Biol       Date:  2004-06-12       Impact factor: 4.304

9.  Modulation of proteases and their inhibitors in immortal human osteoblast-like cells by tumor necrosis factor-alpha in vitro.

Authors:  F S Panagakos; S Kumar
Journal:  Inflammation       Date:  1994-06       Impact factor: 4.092

10.  Haemostatic factors associated with vascular thrombosis in patients with systemic lupus erythematosus and the lupus anticoagulant.

Authors:  T Mayumi; K Nagasawa; T Inoguchi; Y Yamauchi; Y Ishii; Y Tada; F Umeda; Y Niho
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.